{"doc_id": "33545096", "type of study": "Therapy", "title": "", "abstract": "Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.\nAzithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatory actions.\nWe aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.\nIn this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospital with COVID-19 in the UK.\nThe trial is underway at 176 hospitals in the UK.\nEligible and consenting patients were randomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once per day by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatment groups).\nPatients were assigned via web-based simple (unstratified) randomisation with allocation concealment and were twice as likely to be randomly assigned to usual care than to any of the active treatment groups.\nParticipants and local study staff were not masked to the allocated treatment, but all others involved in the trial were masked to the outcome data during the trial.\nThe primary outcome was 28-day all-cause mortality, assessed in the intention-to-treat population.\nThe trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.\nBetween April 7 and Nov 27, 2020, of 16\u2008442 patients enrolled in the RECOVERY trial, 9433 (57%) were eligible and 7763 were included in the assessment of azithromycin.\nThe mean age of these study participants was 65\u00b73 years (SD 15\u00b77) and approximately a third were women (2944 [38%] of 7763).\n2582 patients were randomly allocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone.\nOverall, 561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days (rate ratio 0\u00b797, 95% CI 0\u00b787-1\u00b707; p=0\u00b750).\nNo significant difference was seen in duration of hospital stay (median 10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days (rate ratio 1\u00b704, 95% CI 0\u00b798-1\u00b710; p=0\u00b719).\nAmong those not on invasive mechanical ventilation at baseline, no significant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilation or death (risk ratio 0\u00b795, 95% CI 0\u00b787-1\u00b703; p=0\u00b724).\nIn patients admitted to hospital with COVID-19, azithromycin did not improve survival or other prespecified clinical outcomes.\nAzithromycin use in patients admitted to hospital with COVID-19 should be restricted to patients in whom there is a clear antimicrobial indication.\nUK Research and Innovation (Medical Research Council) and National Institute of Health Research.\nCopyright \u00a9 2021 The Author(s).\nPublished by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.\nPublished by Elsevier Ltd.. All rights reserved.\n", "Evidence Map": {"Enrollment": [{"term": "admitted to hospital", "negation": "affirmed", "UMLS": {}, "start": 25, "end": 45}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 51, "end": 59}, {"term": "admitted to hospital", "negation": "affirmed", "UMLS": {}, "start": 73, "end": 93}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 99, "end": 107}, {"term": "admitted to hospital", "negation": "affirmed", "UMLS": {}, "start": 12, "end": 32}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 38, "end": 46}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Azithromycin in patients admitted to hospital with COVID-19 ( RECOVERY ) : a randomised , controlled , open-label , platform trial .", "Evidence Elements": {"Participant": [{"term": "admitted to hospital", "negation": "affirmed", "UMLS": {}, "start": 25, "end": 45}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 51, "end": 59}], "Intervention": [{"term": "Azithromycin", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 12}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatory actions .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19 .", "Evidence Elements": {"Participant": [{"term": "admitted to hospital", "negation": "affirmed", "UMLS": {}, "start": 73, "end": 93}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 99, "end": 107}], "Intervention": [{"term": "azithromycin", "negation": "affirmed", "UMLS": {}, "start": 48, "end": 60}], "Outcome": [{"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 25, "end": 31}, {"term": "efficacy", "negation": "affirmed", "UMLS": {}, "start": 36, "end": 44}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "In this randomised , controlled , open-label , adaptive platform trial ( Randomised Evaluation of COVID-19 Therapy [ RECOVERY ] ) , several possible treatments were compared with usual care in patients admitted to hospital with COVID-19 in the UK .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "usual care", "negation": "affirmed", "UMLS": {}, "start": 179, "end": 189}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The trial is underway at 176 hospitals in the UK .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Eligible and consenting patients were randomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once per day by mouth or intravenously for 10 days or until discharge ( or allocation to one of the other RECOVERY treatment groups ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "usual standard of care alone", "negation": "affirmed", "UMLS": {}, "start": 67, "end": 95}, {"term": "usual standard of care plus azithromycin", "negation": "affirmed", "UMLS": {}, "start": 99, "end": 139}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Patients were assigned via web-based simple ( unstratified ) randomisation with allocation concealment and were twice as likely to be randomly assigned to usual care than to any of the active treatment groups .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "usual care", "negation": "affirmed", "UMLS": {}, "start": 155, "end": 165}, {"term": "active", "negation": "affirmed", "UMLS": {}, "start": 185, "end": 191}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Participants and local study staff were not masked to the allocated treatment , but all others involved in the trial were masked to the outcome data during the trial .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The primary outcome was 28-day all-cause mortality , assessed in the intention-to-treat population .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "28-day all-cause mortality", "negation": "affirmed", "UMLS": {}, "start": 24, "end": 50}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The trial is registered with ISRCTN , 50189673 , and ClinicalTrials.gov , NCT04381936 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "Between April 7 and Nov 27 , 2020 , of 16 442 patients enrolled in the RECOVERY trial , 9433 ( 57 % ) were eligible and 7763 were included in the assessment of azithromycin .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "The mean age of these study participants was 65\u00b73 years ( SD 15\u00b77 ) and approximately a third were women ( 2944 [ 38 % ] of 7763 ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "2582 patients were randomly allocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "azithromycin", "negation": "affirmed", "UMLS": {}, "start": 49, "end": 61}, {"term": "usual care alone", "negation": "affirmed", "UMLS": {}, "start": 107, "end": 123}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "Overall , 561 ( 22 % ) patients allocated to azithromycin and 1162 ( 22 % ) patients allocated to usual care died within 28 days ( rate ratio 0\u00b797 , 95 % CI 0\u00b787-1\u00b707 ; p=0\u00b750 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "azithromycin", "negation": "affirmed", "UMLS": {}, "start": 45, "end": 57}, {"term": "usual care", "negation": "affirmed", "UMLS": {}, "start": 98, "end": 108}], "Outcome": [{"term": "died", "negation": "affirmed", "UMLS": {}, "start": 109, "end": 113}], "Observation": [], "Count": [{"term": "561 ( 22 % ) patients", "negation": "affirmed", "UMLS": {}, "start": 10, "end": 31}, {"term": "1162 ( 22 % ) patients", "negation": "affirmed", "UMLS": {}, "start": 62, "end": 84}]}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "No significant difference was seen in duration of hospital stay ( median 10 days [ IQR 5 to > 28 ] vs 11 days [ 5 to > 28 ] ) or the proportion of patients discharged from hospital alive within 28 days ( rate ratio 1\u00b704 , 95% CI 0\u00b798-1\u00b710 ; p=0\u00b719 ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "duration of hospital stay", "negation": "negated", "UMLS": {}, "start": 38, "end": 63}, {"term": "proportion of patients discharged from hospital alive within 28", "negation": "negated", "UMLS": {}, "start": 133, "end": 196}], "Observation": [{"term": "significant difference", "negation": "affirmed", "UMLS": {}, "start": 3, "end": 25}], "Count": []}, "Evidence Propositions": [{"Intervention": [], "Observation": "significant difference", "Outcome": "duration of hospital stay", "Count": ""}, {"Intervention": [], "Observation": "significant difference", "Outcome": "proportion of patients discharged from hospital alive within 28", "Count": ""}]}, {"Section": "FINDINGS", "Text": "Among those not on invasive mechanical ventilation at baseline , no significant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilation or death ( risk ratio 0\u00b795 , 95 % CI 0\u00b787-1\u00b703 ; p=0\u00b724 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "invasive mechanical ventilation", "negation": "negated", "UMLS": {}, "start": 19, "end": 50}], "Outcome": [{"term": "proportion meeting the composite endpoint of invasive mechanical ventilation or death", "negation": "negated", "UMLS": {}, "start": 107, "end": 192}], "Observation": [{"term": "significant difference", "negation": "affirmed", "UMLS": {}, "start": 68, "end": 90}], "Count": []}, "Evidence Propositions": [{"Intervention": ["invasive mechanical ventilation"], "Observation": "significant difference", "Outcome": "proportion meeting the composite endpoint of invasive mechanical ventilation or death", "Count": ""}]}, {"Section": "INTERPRETATION", "Text": "In patients admitted to hospital with COVID-19 , azithromycin did not improve survival or other prespecified clinical outcomes .", "Evidence Elements": {"Participant": [{"term": "admitted to hospital", "negation": "affirmed", "UMLS": {}, "start": 12, "end": 32}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 38, "end": 46}], "Intervention": [{"term": "azithromycin", "negation": "affirmed", "UMLS": {}, "start": 49, "end": 61}], "Outcome": [{"term": "survival", "negation": "negated", "UMLS": {}, "start": 78, "end": 86}, {"term": "prespecified clinical", "negation": "negated", "UMLS": {}, "start": 96, "end": 117}], "Observation": [{"term": "improve", "negation": "negated", "UMLS": {}, "start": 70, "end": 77}], "Count": []}, "Evidence Propositions": []}, {"Section": "INTERPRETATION", "Text": "Azithromycin use in patients admitted to hospital with COVID-19 should be restricted to patients in whom there is a clear antimicrobial indication .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FUNDING", "Text": "UK Research and Innovation ( Medical Research Council ) and National Institute of Health Research .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2021 The Author (s ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Published by Elsevier Ltd . This is an Open Access article under the CC BY 4.0 license .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Published by Elsevier Ltd . . All rights reserved .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}